Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.

View in: PubMed

subject areas

Antihypertensive Agents
Blood Pressure Monitoring, Ambulatory
Double-Blind Method
Endothelin Receptor Antagonists
Humans
Hypertension
Treatment Outcome

authors with profiles

George Bakris